Editorial - Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

BERKELEY, CA (UroToday.com) - Src kinase is a non-receptor tyrosine kinase known to be upregulated in castration-resistant prostate cancer (CRPC).

Login to read more...

Written by Christopher P. Evans, MD, a Contributing Editor with UroToday.

UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence About The Editors | About Us | Contact Us | Report an Inaccuracy | Sponsorship Opportunities | Terms of Use Privacy Policy | © 2010 UroToday ® All Rights Reserved